Experimental Agent Ameliorates OAB
MILAN—New data demonstrate that the investigational agent fesoterodine, at both the 4 or 8 mg per day dose, is associated with significant improvements in overactive bladder (OAB) symptoms.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.